BK viral infection after renal transplantation

Česká verzia

Authors: E. Novotná ¹; O. Viklický ^1,2
Authors place of work: Transplantační laboratoř, Pracoviště experimentální medicíny IKEM Praha, vedoucí doc. MUDr. Ondřej Viklický, CSc. ¹; Klinika nefrologie Transplantačního centra IKEM, Praha, přednosta prof. MUDr. Vladimír Teplan, DrSc. ²
Published in the journal: Vnitř Lék 2008; 54(9): 835-841
Category: Review

Summary

Viral infections have been a subject of great interest in patients after organ transplantations. Post‑transplant immunosuppressive therapy is often associated with transfenction or reactivation of viruses. The human polyomavirus type I, also called BK virus (BKV), causes polyomavirus‑associated nephropathy (PVAN) in 1–10% of renal transplant recipients. Thanks to increased PVAN awareness and improved diagnostic techniques, the rate of graft loss has lowered, more consistently in centres with active screening and intervention programs. The risk factors for PVAN are not conclusively defined and likely involve complementing determinants of recipient, graft, and virus. Central element seems to be the failing balance between BKV replication and BKV-specific immune control, which can result from intense triple immunosuppression, HLA‑mismatches, prior rejection and anti‑rejection treatment, or BKV-seropositive donor/seronegative recipient pairs. PVAN diagnosis requires the evaluation of a renal biopsy showing polyomavirus cytopathic changes and confirming BKV through an ancillary technique such as immunohistochemistry. The success rate of the intervention is increased with earlier diagnosis. Therefore, it is recommended that all renal transplant recipients should be screened for BKV replication in urine and serum. The treatment of BKVN consists mainly of reduction in immunosuppressive therapy. Currently, in the clinical management of PVAN, no satisfactory antiviral treatment has been defined. Retransplantation after renal allograft loss to PVAN remains a treatment option for patients clearing polyomavirus replication.

Key words:
BK virus – polyoma virus – PVAN – renal transplantation

Zdroje

1. Gardner SD, Field AM, Coleman DV et al. New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet 1971; 1: 1253–1257.

2. Markowitz RB, Dynan WS. Binding of cellular proteins to the regulatory region of BK virus DNA. J Virol 1988; 62: 3388–3398.

3. Hariharan S. BK virus nephritis after renal transplantation. Kidney Int 2006; 69: 655–662.

4. Randhawa P, Brennan DC. BK virus infection in transplant recipients: an overview and update. Am J Transplant 2006; 6: 2000–2005.

5. Gardner SD, MacKenzie EF, Smith C et al. Prospective study of the human polyomaviruses BK and JC and cytomegalovirus in renal transplant recipients. J Clin Pathol 1984; 37: 578–586.

6. Ramos E, Vincenti F, Lu WX et al. Retransplantation in patients with graft loss caused by polyoma virus nephropathy. Transplantation 2004; 77: 131–133.

7. Allander T, Andreasson K, Gupta S et al. Identification of a third human polyomavirus. J Virol 2007; 81: 4130–4136.

8. Herman J, Van Ranst M, Snoeck R et al. Polyomavirus infection in pediatric renal transplant recipients: evaluation using a quantitative real‑time PCR technique. Pediatr Transplant 2004; 8: 485–492.

9. Howley PM, Khoury G, Byrne JC et al. Physical map of the BK virus genome. J Virol 1975; 16: 959–973.

10. Ramos E, Drachenberg CB, Papadimitriou JC et al. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 2002; 13: 2145–2151.

11. Hirsch HH. BK virus: opportunity makes a pathogen. Clin Infect Dis 2005; 41: 354–360.

12. Dugan AS, Eash S, Atwood WJ. Update on BK virus entry and intracellular trafficking. Transpl Infect Dis 2006; 8: 62–67.

13. Moriyama T, Marquez JP, Wakatsuki T et al. Caveolar endocytosis is critical for BK virus infection of human renal proximal tubular epithelial cells. J Virol 2007; 81: 8552–8562.

14. Drachenberg CB, Papadimitriou JC, Wali R et al. BK polyoma virus allograft nephropathy: ultrastructural features from viral cell entry to lysis. Am J Transplant 2003; 3: 1383–1392.

15. Eash S, Atwood WJ. Involvement of cytoskeletal components in BK virus infectious entry. J Virol 2005; 79: 11734–11741.

16. Dolei A, Pietropaolo V, Gomes E et al. Polyomavirus persistence in lymphocytes: prevalence in lymphocytes from blood donors and healthy personnel of a blood transfusion centre. J Gen Virol 2000; 81: 1967–1973.

17. Griffin MD KH, Larson TS et al. Influence of recipient age and donor gender on polyomavirus‑associated nephropathy rate in recent kidney transplant recipients. Abstract WTC 06L1868, 2006.

18. Hirsch HH, Brennan DC, Drachenberg CB et al. Polyomavirus‑associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 2005; 79: 1277–1286.

19. Nickeleit V, Mihatsch MJ. Polyomavirus nephropathy in native kidneys and renal allografts: an update on an escalating threat. Transpl Int 2006; 19: 960–973.

20. Bohl DL, Storch GA, Ryschkewitsch C et al. Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. Am J Transplant 2005; 5: 2213–2221.

21. Vasudev B, Hariharan S, Hussain SA et al. BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients. Kidney Int 2005; 68: 1834–1839.

22. Brennan DC, Agha I, Bohl DL et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005; 5: 582–594.

23. Hirsch HH, Knowles W, Dickenmann M et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002; 347: 488–496.

24. Park SB, Kwak JH, Lee KT et al. Polyoma virus‑associated nephropathy and concurrent cytomegalovirus infection in the kidney transplant recipients. Transplant Proc 2006; 38: 2059–2061.

25. Comoli P, Binggeli S, Ginevri F et al. Polyomavirus‑associated nephropathy: update on BK virus-specific immunity. Transpl Infect Dis 2006; 8: 86–94.

26. Schwartz SE, Twining LM. BK virus infection in kidney transplantation: a case for early intervention. Prog Transplant 2006; 16: 133–137.

27. Drachenberg CB, Papadimitriou JC. Polyomavirus‑associated nephropathy: update in diagnosis. Transpl Infect Dis 2006; 8: 68–75.

28. Ramos E, Hirsch HH. Polyomavirus‑associated nephropathy: updates on a persisting challenge. Transpl Infect Dis 2006; 8: 59–61.

29. Hirsch HH DC, Ramos E et al. BK viremia lever strongly correlates with the extent/pattern of viral nephropathy. Abstract WTC06L 1168, 2006.

30. Faguer S, Hirsch HH, Kamar N et al. Leflunomide treatment for polyomavirus BK‑associated nephropathy after kidney transplantation. Transpl Int 2007; 20: 962–969.

31. Haškovec C. Kvantitativní reverzně transkriptázová PCR. Manuál ke kurzu RT‑PCR. Duben 2003.

32. Higuchi R, Fockler C, Dollinger G et al. Kinetic PCR analysis: real‑time monitoring of DNA amplification reactions. Biotechnology (N Y) 1993; 11: 1026–1030.

33. Prosser SE, Orentas RJ, Jurgens L et al. Recovery of BK virus large T-antigen-specific cellular immune response correlates with resolution of bk virus nephritis. Transplantation 2008; 85: 185–192.

34. Binggeli S, Egli A, Dickenmann M et al. BKV replication and cellular immune responses in renal transplant recipients. Am J Transplant 2006; 6: 2218–2220.

35. Trofe J, Hirsch HH, Ramos E. Polyomavirus‑associated nephropathy: update of clinical management in kidney transplant patients. Transpl Infect Dis 2006; 8: 76–85.

36. Mindlova M, Boucek P, Saudek F et al. Kidney retransplantation following graft loss to polyoma virus‑associated nephropathy: an effective treatment option in simultaneous pancreas and kidney transplant recipients. Transpl Int 2007; 21: 353–356.